Search results
AstraZeneca's (AZN) Truqap Misses Endpoints in TNBC Study
Zacks via Yahoo Finance· 19 hours agoAstraZeneca's (AZN) phase III CAPItello-290 study evaluating Truqap plus chemotherapy in patients...
CAR T cell therapy for advanced prostate cancer demonstrates positive results in Phase I clinical...
Medical Xpress· 7 days agoThe trial treated 14 prostate stem cell antigen (PSCA)-positive patients who had metastatic castration resistant prostate cancer ...
America first declared war on cancer half a century ago. Today’s regulatory hurdles won’t help us...
Fortune via Yahoo Finance· 20 hours agoExciting new technologies can help the U.S. government win the war that it declared 50 years ago—but...
AstraZeneca's Advanced Breast Cancer Drug Fails to Meet Primary Goals
Morningstar· 1 day agoAstraZeneca said a late-stage study showed that its therapy for advanced or metastatic triple-negative breast cancer didn't meet its primary goals. The ...
Opinion | I Tried to Protect My Mother From Dying in Pain. The Law Robbed Her of That Dignity.
MedPage Today· 3 days agoWhen my mother was 56 years old, she found out that her father had metastatic prostate cancer. The ...
AstraZeneca's Combination Cancer Drug For Advanced Breast Cancer Study Flunks Late-Stage Trial -...
Benzinga· 21 hours agoTuesday, AstraZeneca Plc AZN announced topline data from the CAPItello-290 Phase 3 trial for Truqap...
Study demonstrates how AI can develop more personalized cancer treatment strategies
Medical Xpress· 2 days ago...In a study, titled "Mathematical Model-Driven Deep Learning Enables Personalized Adaptive Therapy" published in Cancer Research, researchers from the University of Oxford and Moffitt Cancer Center in Florida introduce a novel framework that applies deep reinforcement learning, DRL, (a form of AI)...
What do we know about Kate's cancer treatment?
BBC via AOL· 5 days agoHow many people get cancer? In the UK, one in two people develop some kind of cancer during their lifetime. There are more than 200 different types of &...
FDA Expands Repotrectinib Label
Medscape· 6 days agoThe new accelerated approval for the TKI was based on the overall response rate in 48 patients.
Knight Therapeutics Inc. (TSE:GUD) Senior Officer Amal Khouri Sells 20,000 Shares
ETF DAILY NEWS· 4 days agoKnight Therapeutics Inc. (TSE:GUD – Get Free Report) Senior Officer Amal Khouri sold 20,000 shares of the company’s stock in a transaction on Monday, June 10th. The shares were sold at an average ...